Join Growin Stock Community!

心誠鎂6934.TW Overview

TW StockBiotech. & Medical
(No presentation for 6934)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

心誠鎂（6934）Overall Performance

心誠鎂（6934）AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

心誠鎂（6934） PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

心誠鎂（6934）Key Information

心誠鎂（6934）Profile

HCmed Innovations Co Ltd. provides platforms for inhalation therapy using mesh technology. Its products include Pulmogine and AdheResp. The firm offers comprehensive aerosol characterization analytical services to support the development and optimization of inhalation products. It also offers analytical support in compliance with Pharmacopoeia guidelines. The company was founded by Jason Cheng, Leon Tsai, Shaogi Huang and Simon Hsieh on October 06, 2014 and is headquartered in Taipei, Taiwan.

心誠鎂（6934）FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-4.56
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
24.01
PB Ratio
14.23
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
53.67%
Net Margin
-103.70%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-4.56
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
24.01
PB Ratio
14.23
Price-to-FCF
-
Gross Margin
53.67%
Net Margin
-103.70%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is 6934's latest earnings report released?

    The most recent financial report for 心誠鎂 (6934) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 6934's short-term business performance and financial health. For the latest updates on 6934's earnings releases, visit this page regularly.

  • What is the operating profit of 6934?

    According to the latest financial report, 心誠鎂 (6934) reported an Operating Profit of -37.09M with an Operating Margin of -537.63% this period, representing a decline of 77.48% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is 6934's revenue growth?

    In the latest financial report, 心誠鎂 (6934) announced revenue of 6.9M, with a Year-Over-Year growth rate of -60.74%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does 6934 have?

    At the end of the period, 心誠鎂 (6934) held Total Cash and Cash Equivalents of 25.88M, accounting for 0.07 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does 6934 go with three margins increasing?

    In the latest report, 心誠鎂 (6934) did not achieve the “three margins increasing” benchmark, with a gross margin of -131.73%%, operating margin of -537.63%%, and net margin of -523.7%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 6934's profit trajectory and future growth potential.

  • Is 6934's EPS continuing to grow?

    According to the past four quarterly reports, 心誠鎂 (6934)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -1.1. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

default symbol

6934

心誠鎂

105.50D

-10.90%

(-0.11)